Vanessa C. Williams
About
Vanessa C. Williams is a scholar working on Infectious Diseases, Virology and Physiology.
According to data from OpenAlex, Vanessa C. Williams has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 10 papers in Virology and 7 papers in Physiology. Recurrent topics in Vanessa C. Williams's work include HIV Research and Treatment (10 papers), HIV/AIDS drug development and treatment (10 papers) and Asthma and respiratory diseases (6 papers). Vanessa C. Williams is often cited by papers focused on HIV Research and Treatment (10 papers), HIV/AIDS drug development and treatment (10 papers) and Asthma and respiratory diseases (6 papers). Vanessa C. Williams collaborates with scholars based in United States, Netherlands and United Kingdom. Vanessa C. Williams's co-authors include Dorothy J. Margolskee, Jules I. Schwartz, Patrick Manning, Richard M. Watson, Paul M. O’Byrne, Jaime E. Hernández, Robin L. Fisher, J Tyler Lonergan, Grace A. McComsey and William W. Busse and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Vanessa C. Williams
32 papers receiving 1.4k citations
Peers
Vanessa C. Williams
Henrik F. Thomsen Denmark
Johnson Haynes United States
Yijun Yang United States
Kim Nguyen South Africa
Arthur C. Theodore United States
Dipen Patel United States
Paul Rafferty United Kingdom
Giuseppe Fiorentino Italy
Wolfgang Stöhr United Kingdom
G Leitz United States
Citations per year, relative to Vanessa C. Williams Vanessa C. Williams (= 1×)
peers
Henrik F. Thomsen
Countries citing papers authored by Vanessa C. Williams
Since
Specialization
Citations
This map shows the geographic impact of Vanessa C. Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa C. Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa C. Williams more than expected).
Fields of papers citing papers by Vanessa C. Williams
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vanessa C. Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa C. Williams. The network helps show where Vanessa C. Williams may publish in the future.
Co-authorship network of co-authors of Vanessa C. Williams
This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa C. Williams. A scholar is included among the top collaborators of Vanessa C. Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa C. Williams. Vanessa C. Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hamadani, Mehdi, Morton Coleman, Ralph V. Boccia, et al.. (2023). Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL‐102): A phase 1 study. Hematological Oncology. 41(5). 848–857.
2.
Leonard, John P., Stephanie A. Gregory, Hedy Smith, et al.. (2016). CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 16(4). 191–196.
3.
Oers, Marinus H. J. van, Kazimierz Kuliczkowski, Lukáš Smolej, et al.. (2015). Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology. 16(13). 1370–1379.
4.
Cohen, Calvin, Philip S. Brachman, Stefan Schneider, et al.. (2008). Short‐term Safety and Tolerability of a Once‐Daily Fixed‐Dose Abacavir‐Lamivudine Combination versus Twice‐Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 28(3). 314–322.
5.
Pape, Theresa, Allen W. Heinemann, Ann Guernon, et al.. (2006). Establishing a prognosis for functional outcome during coma recovery. Brain Injury. 20(7). 743–758.
6.
Kumar, Princy, Melanie Thompson, Karen T. Tashima, et al.. (2006). A prospective, 96‐week study of the impact of Trizivir®, Combivir®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity. HIV Medicine. 7(2). 85–98.
7.
Ross, Lisa, Ronan Boulmé, Jaime E. Hernández, et al.. (2005). A Direct Comparison of Drug Susceptibility to HIV Type 1 from Antiretroviral Experienced Subjects as Assessed by the Antivirogram and PhenoSense Assays and by Seven Resistance Algorithms. AIDS Research and Human Retroviruses. 21(11). 933–939.
8.
Keiser, Philip, Michael Sension, Edwin DeJesus, et al.. (2005). Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infectious Diseases. 5(1). 2–2.
9.
Lonergan, J Tyler, Grace A. McComsey, Robin L. Fisher, et al.. (2004). Lack of Recurrence of Hyperlactatemia in HIV-Infected Patients Switched From Stavudine to Abacavir or Zidovudine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 36(4). 935–942.
10.
McComsey, Grace A., J Tyler Lonergan, Charles L. Hoppel, et al.. (2004). Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS. 19(1). 15–23.
11.
McComsey, Grace A., Douglas Ward, Michael Sension, et al.. (2004). Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study. Clinical Infectious Diseases. 38(2). 263–270.
12.
Fischl, Margaret A., Charles Farthing, Melanie Thompson, et al.. (2003). Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(11). 1432–1440.
13.
O’Quinn, Stephen, Sara A. Ephross, Vanessa C. Williams, et al.. (1999). Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Archives of Gynecology and Obstetrics. 263(1-2). 7–12.
14.
Schwartz, Jules I., Dorothy J. Margolskee, Thorir D. Bjornsson, et al.. (1993). Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast. British Journal of Clinical Pharmacology. 36(5). 464–466.
15.
Margolskee, Dorothy J., et al.. (1992). Bronchodilation with a Potent and Selective Leukotriene D 4 (LTD 4 ) Receptor Antagonist (MK-571) in Patients with Asthma. American Review of Respiratory Disease. 146(2). 358–363.
16.
Margolskee, Dorothy J., et al.. (1991). Leukotriene (LT) D4 Is Involved in Antigen‐Induced Asthma: a Study with the LTD4 Receptor Antagonist, MK‐571. Annals of the New York Academy of Sciences. 629(1). 436–436.
17.
Manning, Patrick, Richard M. Watson, Dorothy J. Margolskee, et al.. (1990). Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D4–Receptor Antagonist. New England Journal of Medicine. 323(25). 1736–1739.
18.
Liddle, Rodger A., Barry J. Gertz, Shuji Kanayama, et al.. (1990). Regulation of Pancreatic Endocrine Function by Cholecystokinin: Studies with MK-329, a Nonpeptide Cholecystokinin Receptor Antagonist*. The Journal of Clinical Endocrinology & Metabolism. 70(5). 1312–1318.
19.
Warren, J. B., C. T. Dollery, Richard W. Fuller, Vanessa C. Williams, & Barry J. Gertz. (1989). Assessment of MK-912, an α2-adrenoceptor antagonist, with use of intravenous clonidine. Clinical Pharmacology & Therapeutics. 46(1). 103–109.
20.
Gertz, Barry J., Peter H. Vlasses, Mario L. Rocci, et al.. (1989). Clinical evaluation of a benzofuroquinolizine α2-adrenoceptor antagonist. Clinical Pharmacology & Therapeutics. 46(5). 566–575.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Henrik F. Thomsen Breakdown of academic impact, for papers by Johnson Haynes Breakdown of academic impact, for papers by Yijun Yang Breakdown of academic impact, for papers by Kim Nguyen Breakdown of academic impact, for papers by Arthur C. Theodore Breakdown of academic impact, for papers by Dipen Patel Breakdown of academic impact, for papers by Paul Rafferty Breakdown of academic impact, for papers by Giuseppe Fiorentino Breakdown of academic impact, for papers by Wolfgang Stöhr Breakdown of academic impact, for papers by G Leitz